Industry Insights · Industry Bulletin Digest
Polymer Medical Device Bulletin 2025 Issue 1 digest: regulatory reform and annual data
Turning the policies and data scattered in an association bulletin into an original, citable digest.
Annual regulatory tone
This issue records the 2025 national drug and device regulation meetings, plus the 2024 device standards yearbook and the 2024 registration report, sketching that year's regulatory priorities and registration picture.
Citable key data
- 2024 consumable first-registration localization rate reached 95%;
- favorable device signals around the 'Two Sessions';
- State Council Office No. 53 (2024): deepen drug/device regulatory reform and promote high-quality development.
Regulatory and standards updates
It also covers the GMP revision draft consultation, device clinical-trial inspection key points and judgment principles, and the review center's stepped-up support for innovative devices — helping firms gauge compliance and filing pace.
The BIO angle
FAQ
What's the most citable figure in this issue?
The 2024 consumable first-registration localization rate of 95%, a key gauge of substitution progress.
What is State Council Office No. 53?
The 2024 opinion on deepening drug and device regulatory reform and promoting high-quality industry development — a guiding document for that reform phase.
Who publishes the bulletin?
The Medical Polymer Products branch of the China Association for Medical Devices Industry, releasing policy, standards and industry information.
Related reading
- Polymer Medical Device Bulletin 2025 Issue 3 Digest: Procurement Changes and EU Exports | BIO Insights
- Polymer Medical Device Bulletin 2025 Issue 4 Digest: Device Law and Materials Challenge | BIO Insights
- Polymer Medical Device Bulletin 2026 Issue 1 Digest: Annual Highlights and UDI Progress | BIO Insights
Note: an original analysis compiled from public industry information; figures and conclusions per official/original sources. Not investment advice.
Building in China's medical-device market?
From advanced medical silicone/polymers to material selection, regulatory and supply, BIO helps global and local partners move from selection to landed supply in China.